Friday, biopharmaceutical company Emergent BioSolutions, Inc. (EBS), announced that U.S. Food and Drug Administration, or FDA, has approved its supplemental Biologics License Application for Anthrax vaccine adsorbed or BioThrax.
The supplement for BioThrax, the only FDA-licensed vaccine to prevent anthrax, permits five intramuscular doses over the former schedule of six subcutaneous doses.
Emergent stated that the results were based on interim analysis of data from a large multi-center study initiated by Center for Disease Control and Prevention or CDC in 2002. The study evaluated on the dosage levels for effective immune response. Presently, BioThrax is administered over six months with booster doses up to three years apart.
CDC, a part of the US Department of Health and Human Services, will complete further data analysis by 2009. Following which, Emergent may submit the results for further reduction in the number of required BioThrax doses.
BioThrax is licensed by FDA as a pre-exposure prophylaxis for use in adults with high risk of exposure to anthrax spores. Since 1998, the U.S. government has procured nearly 32 million doses of BioThrax.
The Stock closed Thursday, at $25.30 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.